The purpose of this study is to investigate the effects of semaglutide subcutaneous 2.4 mg once-weekly on physical function, symptoms and body weight compared with placebo, both added to standard of care, in subjects with obesity-related HFpEF.
Please use this link for further information:
Primary Investigator: Gregory Egnaczyk